Celgene Corporation announced that nearly 30 combination studies including IMiD® compounds, REVLIMID® (lenalidomide) and POMALYST®/IMNOVID® (pomalidomide), across a range of patient segments within multiple myeloma are being presented at the 57thAmerican Society of Hematology Annual Meeting (ASH).
In the U.S., REVLIMID in combination with dexamethasone is approved for patients with multiple myeloma and POMALYST in combination with dexamethasone is approved for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. These treatments are the subject of important investigational studies in combination with investigational and approved agents.
In the United States , REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma. REVLIMID is also approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 70 countries, encompassing Europe , the Americas , the Middle East and Asia , and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand .
